PD-L1 expression
|
Esophageal Adenocarcinoma
|
PD-L1 expression
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
ESMO-GI 2022 - 5 days (New B)
|
nivolumab Sensitive: B - Late Trials
ESMO-GI 2022 - 5 days - (New B)
|
No biomarker
|
Esophageal Adenocarcinoma
|
No biomarker
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
HER-2 negative + PD-L1 expression
|
Esophageal Adenocarcinoma
|
HER-2 negative + PD-L1 expression
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Adenocarcinoma
|
No biomarker
|
Esophageal Adenocarcinoma
|
ramucirumab Sensitive: A2 - Guideline
|
ramucirumab Sensitive: A2 - Guideline
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Esophageal Adenocarcinoma
|
PD-L1 expression
|
Esophageal Adenocarcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Adenocarcinoma
|
No biomarker
|
Esophageal Adenocarcinoma
|
FP Sensitive: A2 - Guideline
|
FP Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Adenocarcinoma
|
No biomarker
|
Esophageal Adenocarcinoma
|
FLOT Sensitive: A2 - Guideline
|
FLOT Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Adenocarcinoma
|
No biomarker
|
Esophageal Adenocarcinoma
|
FOLFOX Sensitive: A2 - Guideline
|
FOLFOX Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
PD-L1 overexpression
|
Esophageal Adenocarcinoma
|
PD-L1 overexpression
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 underexpression
|
Esophageal Adenocarcinoma
|
PD-L1 underexpression
|
Esophageal Adenocarcinoma
|
Immunotherapy Resistant: B - Late Trials
|
Immunotherapy Resistant: B - Late Trials
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
trastuzumab + pertuzumab Sensitive: C1 - Off-label
|
trastuzumab + pertuzumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Esophageal Adenocarcinoma
|
MSI-H/dMMR
|
Esophageal Adenocarcinoma
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
CLDN18.2 expression
|
Esophageal Adenocarcinoma
|
CLDN18.2 expression
|
Esophageal Adenocarcinoma
|
IMAB362 Sensitive: C2 – Inclusion Criteria
|
IMAB362 Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Esophageal Adenocarcinoma
|
HER-2 amplification
|
Esophageal Adenocarcinoma
|
trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
paclitaxel Resistant: C3 – Early Trials
|
paclitaxel Resistant: C3 – Early Trials
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
carboplatin Resistant: C3 – Early Trials
|
carboplatin Resistant: C3 – Early Trials
|
ARID1A mutation
|
Esophageal Adenocarcinoma
|
ARID1A mutation
|
Esophageal Adenocarcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
DKK1 overexpression
|
Esophageal Adenocarcinoma
|
DKK1 overexpression
|
Esophageal Adenocarcinoma
|
pembrolizumab + DKN-01 Sensitive: C3 – Early Trials
|
pembrolizumab + DKN-01 Sensitive: C3 – Early Trials
|
DKK1 overexpression
|
Esophageal Adenocarcinoma
|
DKK1 overexpression
|
Esophageal Adenocarcinoma
|
DKN-01 Sensitive: C3 – Early Trials
|
DKN-01 Sensitive: C3 – Early Trials
|
GRB7 positive
|
Esophageal Adenocarcinoma
|
GRB7 positive
|
Esophageal Adenocarcinoma
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
ERCC1 negative
|
Esophageal Adenocarcinoma
|
ERCC1 negative
|
Esophageal Adenocarcinoma
|
SOX Sensitive: C3 – Early Trials
|
SOX Sensitive: C3 – Early Trials
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
nivolumab + trastuzumab Sensitive: C3 – Early Trials
|
nivolumab + trastuzumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Esophageal Adenocarcinoma
|
PD-L1 overexpression
|
Esophageal Adenocarcinoma
|
durvalumab Sensitive: C3 – Early Trials
|
durvalumab Sensitive: C3 – Early Trials
|
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
|
Esophageal Adenocarcinoma
|
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
|
Esophageal Adenocarcinoma
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|
TP53 mutation
|
Esophageal Adenocarcinoma
|
TP53 mutation
|
Esophageal Adenocarcinoma
|
APR-246 Sensitive: D – Preclinical
|
APR-246 Sensitive: D – Preclinical
|